Opinion | Published:

Hit and lead criteria in drug discovery for infectious diseases of the developing world

Nature Reviews Drug Discovery volume 14, pages 751758 (2015) | Download Citation

Abstract

Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishmaniasis and Chagas disease. Here, we present the agreed criteria and discuss the underlying rationale.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    World Health Organization. Antimicrobial resistance: global report on surveillance 2014 (WHO, 2014).

  2. 2.

    , & High-throughput screening: the hits and leads of drug discovery — an overview. J. Appl. Pharma. Sci. 1, 2–10 (2011).

  3. 3.

    Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov. Today 17, 1088–1102 (2012).

  4. 4.

    & Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5, 941–955 (2006).

  5. 5.

    et al. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop. Dis. 3, e440 (2009).

  6. 6.

    , , , & Designing the next generation of medicines for malaria control and eradication. Malar. J. 12, 187 (2013).

  7. 7.

    Phenotypic versus target-based drug discovery for first-in-class medicines. Clin. Pharmacol. Ther. 93, 299–301 (2013).

  8. 8.

    , & The discovery of first-in-class drugs: origins and evolution. Nat. Rev. Drug Discov. 13, 577–587 (2014).

  9. 9.

    , , & Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40 (2007).

  10. 10.

    et al. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J. Med. Chem. 57, 5381–5394 (2014).

  11. 11.

    Cultivation of Plasmodium spp. Clin. Microbiol. Rev. 15, 355–364 (2002).

  12. 12.

    & Apoptosis stalks Plasmodium falciparum maintained in continuous culture condition. Malar J. 9 (Suppl. 3), S6 (2010).

  13. 13.

    Chagas disease drug discovery: toward a new era. J. Biomol. Screen 20, 22–35 (2015).

  14. 14.

    , & Malaria medicines: a glass half full? Nat. Rev. Drug Discov. 14, 1–18 (2015).

  15. 15.

    & A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am. J. Trop. Med. Hyg. 77, 193–197 (2007).

  16. 16.

    , & New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther. Clin. Risk Manag. 10, 597–602 (2014).

  17. 17.

    & Delamanid: a new armor in combating drug-resistant tuberculosis. J. Pharmacol. Pharmacother. 5, 222–224 (2014).

  18. 18.

    et al. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today 11, 175–180 (2006).

  19. 19.

    et al. Early drug discovery and development guidelines: for academic researchers, collaborators, and start-up companies. Assay Guidance Manual , (2012).

  20. 20.

    et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50–55 (2014).

  21. 21.

    et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411–423 (2014).

  22. 22.

    Microbiology: malaria runs rings round artemisinin. Nature 520, 628–630 (2015).

  23. 23.

    et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520, 683–687 (2015).

  24. 24.

    & in Third World Diseases (ed. Elliot, R. L.) 125–180 (Springer, 2011).

  25. 25.

    et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305–310 (2010).

  26. 26.

    et al. Chemical genetics of Plasmodium falciparum. Nature 465, 311–315 (2010).

  27. 27.

    et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl Acad. Sci. USA 105, 9059–9064 (2008).

  28. 28.

    et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372–1377 (2011).

  29. 29.

    et al. A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS ONE 3, e2252 (2008).

  30. 30.

    et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci. Transl. Med. 5, 177ra37 (2013).

  31. 31.

    & Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol. 15, 544 (2014).

  32. 32.

    et al. Novel mutations in K13 propeller gene of artemisinin-resistant Plasmodium falciparum. Emerg. Infect. Dis. 21, 490–492 (2015).

  33. 33.

    et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect. Dis. 15, 415–421 (2015).

  34. 34.

    et al. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS ONE 6, e18162 (2011).

  35. 35.

    , , & The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies. Malar J. 11, 70 (2012).

  36. 36.

    World Health Organization. Global tuberculosis report 2014. WHO , (2014).

  37. 37.

    et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36, 362–366 (1998).

  38. 38.

    et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 1380–1385 (2007).

  39. 39.

    et al. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7, 1190–1197 (2012).

  40. 40.

    In vitro model of hypoxically induced nonreplicating persistence of Mycobacterium tuberculosis. Methods Mol. Med. 54, 247–269 (2001).

  41. 41.

    et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J. Antimicrob. Chemother. 70, 857–867 (2015).

  42. 42.

    & Microbial phenotypic heterogeneity and antibiotic tolerance. Curr. Opin. Microbiol. 10, 30–38 (2007).

  43. 43.

    The search for new sterilizing anti-tuberculosis drugs. Front. Biosci. 9, 1059–1072 (2004).

  44. 44.

    et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 92, 453–488 (2012).

  45. 45.

    et al. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 693–697 (2015).

  46. 46.

    et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157–1160 (2013).

  47. 47.

    , , , & Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol. 10, 943–948 (2009).

  48. 48.

    et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205, 595–602 (2012).

  49. 49.

    et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc. Natl Acad. Sci. USA 112, 1827–1832 (2015).

  50. 50.

    , & New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol. Rev. 264, 344–362 (2015).

  51. 51.

    & Treatment of visceral leishmaniasis. J. Glob. Infect. Dis. 2, 151–158 (2010).

  52. 52.

    & An update on pharmacotherapy for leishmaniasis. Expert Opin. Pharmacother. 16, 237–252 (2014).

  53. 53.

    et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N. Engl. J. Med. 370, 1899–1908 (2014).

  54. 54.

    et al. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob. Agents Chemother. 57, 2913–2922 (2013).

  55. 55.

    et al. Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Future Med. Chem. 5, 1733–1752 (2013).

  56. 56.

    et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci. Rep. 5, 8771 (2015).

  57. 57.

    & Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 141, 140–146 (2014).

  58. 58.

    , , & Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).

  59. 59.

    Drug discovery for neglected diseases: molecular target-based and phenotypic approaches. J. Med. Chem. 56, 7719–7726 (2013).

  60. 60.

    et al. Malaria and artemisinin derivatives: an updated review. Mini Rev. Med. Chem. 13, 1879–1902 (2013).

  61. 61.

    Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod. Toxicol. 28, 285–296 (2009).

  62. 62.

    Safety of artemisinin antimalarials. Clin. Infect. Dis. 42, 1214–1215 (2006).

  63. 63.

    et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319, 998–1008 (2006).

  64. 64.

    & Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod. 67, 129–135 (2004).

  65. 65.

    , , & Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12, 112–124 (2007).

  66. 66.

    History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin. Wochenschr. 114, 433–437 (2002).

  67. 67.

    & The Global Health Innovative Technology (GHIT) fund: financing medical innovations for neglected populations. Lancet Glob. Health 1, e184–185 (2013).

  68. 68.

    The GHIT fund shows its cards. Nat. Rev. Drug Discov. 12, 894 (2013).

  69. 69.

    & Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc. Jpn Acad., Ser. B 87, 13–28 (2011).

  70. 70.

    , & Advances in drug discovery and biochemical studies. Trends Parasitol. 23, 223–229 (2007).

  71. 71.

    & The life and times of ivermectin - a success story. Nat. Rev. Microbiol. 2, 984–989 (2004).

  72. 72.

    , & Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J. Nat. Prod. 74, 900–907 (2011).

  73. 73.

    A historical perspective on the discovery of statins. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 86, 484–493 (2010).

  74. 74.

    Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2, 517–526 (2003).

  75. 75.

    & New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719–2740 (2010).

  76. 76.

    , , & A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712–1722 (2002).

  77. 77.

    & Chemistry: chemical con artists foil drug discovery. Nature 513, 481–483 (2014).

  78. 78.

    , , & Challenges in antimalarial drug discovery. Future Med. Chem. 3, 1401–1412 (2011).

  79. 79.

    et al. A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs. Antimicrob. Agents Chemother. 58, 7292–7302 (2014).

  80. 80.

    Cellular and genetic mechanisms underlying susceptibility of animal models to tuberculosis infection. Novartis Found. Symp. 217, 112–117; discussion 117–119 (1998).

  81. 81.

    , & Role of hERG potassium channel assays in drug development. Channels (Austin) 2, 87–93 (2008).

  82. 82.

    et al. Cell viability assays. Assay Guidance Manual , (2004).

Download references

Author information

Affiliations

  1. Global Health Innovative Technology (GHIT) Fund, Ark Hills, Sengokuyama Mori Tower (25F), 1-9-10 Roppongi, Minato-ku, Tokyo 106–0032, Japan.

    • Kei Katsuno
    •  & B. T. Slingsby
  2. Medicines for Malaria Venture (MMV), 20, Route de Pré-Bois, 1215 Geneva 15, Switzerland.

    • Jeremy N. Burrows
    • , Rob Hooft van Huijsduijnen
    •  & Dennis Schmatz
  3. Bill & Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98102, USA.

    • Ken Duncan
    •  & Peter Warner
  4. Global Alliance for TB Drug Development (TB Alliance), 40 Wall Street, 24th Floor, New York, New York 10005, USA.

    • Takushi Kaneko
  5. University of Tokyo, 7-3-1, Hongo, Bunkyo, Tokyo 113–0033, Japan.

    • Kiyoshi Kita
  6. Drugs for Neglected Diseases initiative (DNDi), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland.

    • Charles E. Mowbray

Authors

  1. Search for Kei Katsuno in:

  2. Search for Jeremy N. Burrows in:

  3. Search for Ken Duncan in:

  4. Search for Rob Hooft van Huijsduijnen in:

  5. Search for Takushi Kaneko in:

  6. Search for Kiyoshi Kita in:

  7. Search for Charles E. Mowbray in:

  8. Search for Dennis Schmatz in:

  9. Search for Peter Warner in:

  10. Search for B. T. Slingsby in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Kei Katsuno.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd4683

Further reading